Metastatic Cancer Clinical Trials in Chicago, Illinois

5 studies are recruiting for metastatic cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

2. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

   This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   126 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT05208047 on ClinicalTrials.gov

3. STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study

   This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to up to 10 lesions. After study intervention, participants will undergo ctDNA collection at 8 weeks a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT07269080 on ClinicalTrials.gov

4. Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

   A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood fro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT04295863 on ClinicalTrials.gov

5. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

   Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   11 in total

   Run by

   Qurient Co., Ltd.

   See if you can join NCT05394103 on ClinicalTrials.gov